secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001641172-25-002009
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled
--------------------------------------------------------------------------------

- First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.
- TIGeR-PaC trial: 90 of 114 patients randomized; 50 of 86 events; 2nd interim analysis at 52nd event expected Q2 2025.
- Cash $7.2M at 2024 year-end; $10.9M net raised in Feb 2025 public offering.
- Net loss $8.8M in 2024 vs $10.2M in 2023; R&D $6.0M, SG&A $5.0M.
- Shares outstanding 36.5M as of March 25, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000164117225002009/0001641172-25-002009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000164117225002009/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer